☆ 4.8 Article

Host chitinase 3-like-1 is a universal therapeutic target for SARS-CoV-2 viral variants in COVID-19

ELIFE (2022)

Related references

Note: Only part of the references are listed.

Review Microbiology

Emerging SARS-CoV-2 Variants: Genetic Variability and Clinical Implications

Aakriti Dubey et al.

Summary: The sudden rise in COVID-19 cases in 2020 and the emergence of fast-spreading variants have created a worrisome situation worldwide. New variants with mutations that outcompete existing circulating variants are frequently reported, raising concerns about the efficacy of vaccines, increased transmissibility, immune escape, and diagnostic failures. Although not yet validated, it is believed that SARS-CoV-2 is acquiring new mutations to gain a fitness advantage for rapid transmission or to overcome immune resistance. Significant evolution of SARS-CoV-2 has been observed since its first appearance in 2019, but the impacts of these mutations in many variants have not been analyzed. This article provides a comprehensive review of the emerging variants of SARS-CoV-2, key mutations in the viral genome, and the possible impacts on current prevention and therapeutic strategies.

CURRENT MICROBIOLOGY (2022)

Add to Collection

Article Virology

The K18-Human ACE2 Transgenic Mouse Model Recapitulates Non-severe and Severe COVID-19 in Response to an Infectious Dose of the SARS-CoV-2 Virus

Wenjuan Dong et al.

Summary: The K18-hACE2 mouse model provides a comprehensive analysis of SARS-CoV-2 infection and shows that different viral doses lead to varying degrees of organ damage. This model accurately reproduces both severe and non-severe COVID-19 in humans, making it valuable for drug development.

JOURNAL OF VIROLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

Elisabetta Cameroni et al.

Summary: The Omicron variant of SARS-CoV-2 has raised concerns due to its 37 amino acid substitutions in the spike protein, particularly in the receptor-binding domain (RBD), leading to increased binding affinity with human ACE2. Neutralizing activity against Omicron was greatly reduced in convalescent and vaccinated individuals compared to the ancestral virus, but this decrease was less significant after a third vaccine dose. Broadly neutralizing monoclonal antibodies recognizing conserved RBD epitopes may be crucial in combating the Omicron variant and future zoonotic transmissions.

NATURE (2022)

Add to Collection

Article Multidisciplinary Sciences

Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2

Lihong Liu et al.

Summary: The B.1.1.529/Omicron variant of SARS-CoV-2, initially detected in southern Africa, has rapidly spread globally and is expected to become dominant due to its enhanced transmissibility in the coming weeks. This variant poses a threat to the efficacy of current COVID-19 vaccines and antibody therapies due to its significant antibody resistance. Even individuals who have received vaccines and booster doses may have reduced neutralizing activity against B.1.1.529.

NATURE (2022)

Add to Collection

Article Microbiology

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies

Allison J. Greaney et al.

Summary: The evolution of SARS-CoV-2 may impact the recognition of the virus by human antibody-mediated immunity, with mutations affecting antibody binding varying significantly among individuals and within the same individual over time. Despite this variability, mutations that greatly reduce antibody binding usually occur at specific sites in the RBD, with E484 being the most crucial. These findings can inform surveillance efforts for SARS-CoV-2 evolution in the future.

CELL HOST & MICROBE (2021)

Add to Collection

Article Multidisciplinary Sciences

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Pengfei Wang et al.

Summary: The COVID-19 pandemic has had global repercussions, with promising vaccines and monoclonal antibody therapies. However, newly detected variants of SARS-CoV-2 present challenges to these treatment options.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

Genomic characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi, India

Mahesh S. Dhar et al.

Summary: Delhi experienced multiple severe outbreaks in 2020, reaching a seropositivity rate of >50% by 2021. The Delta variant's high transmissibility and immune evasion led to a surge in cases in Delhi.

SCIENCE (2021)

Add to Collection

Article Medicine, Research & Experimental

Chitinase 3-like-1 is a therapeutic target that mediates the effects of aging in COVID-19

Suchitra Kamle et al.

Summary: CHI3L1 is induced in elderly individuals and patients with comorbid diseases, playing a significant role in stimulating ACE2 and SPP during SC2 infection, and its levels correlate with COVID-19 severity.

JCI INSIGHT (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Discovery of Kasugamycin as a Potent Inhibitor of Glycoside Hydrolase Family 18 Chitinases

Huitang Qi et al.

Summary: Kasugamycin, an aminoglycoside antibiotic, has been found to be a competitive inhibitor of glycoside hydrolase family 18 (GH18) chitinases in various organisms. It was discovered that the electrostatic interaction between kasugamycin and a conserved aspartate in GH18 chitinase is vital for its inhibitory activity. This research not only identifies new molecular targets of kasugamycin but also expands the understanding of GH inhibitor design by utilizing a scaffold unrelated to the substrate.

FRONTIERS IN MOLECULAR BIOSCIENCES (2021)

Add to Collection

Article Biochemistry & Molecular Biology

The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies

Richard Copin et al.

Summary: Monoclonal antibodies against SARS-CoV-2 are clinically validated therapeutic options against COVID-19. Studies show that non-competing antibody combinations in REGEN-COV provide protection against all current variants of concern and prevent the emergence of new variants.

CELL (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Confronting the Delta Variant of SARS-CoV-2, Summer 2021

Carlos del Rio et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Virology

V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity

Junxian Ou et al.

Summary: The COVID-19 pandemic is caused by a novel coronavirus, SARS-CoV-2, with the spike protein receptor-binding domain (RBD) being a critical factor in viral infectivity. Research indicates that certain viral mutations may increase binding affinity to human receptors, but bat SARS-like CoV has difficulty infecting humans, while pangolin CoV may be infectious. The study provides insights into the evolution of early SARS-CoV-2 variants and supports ongoing surveillance of spike mutations for drug and vaccine development.

JOURNAL OF VIROLOGY (2021)

Add to Collection

Letter Medicine, General & Internal

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness

Aziz Sheikh et al.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19

M. P. O'Brien et al.

Summary: The study indicates that subcutaneous REGEN-COV can effectively prevent severe Covid-19 and reduce the duration of symptoms in individuals at high risk for infection due to household exposure to confirmed SARS-CoV-2 cases.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Severe SARS-CoV-2 Breakthrough Reinfection With Delta Variant After Recovery From Breakthrough Infection by Alpha Variant in a Fully Vaccinated Health Worker

Jayanthi Shastri et al.

Summary: The study found that despite post-vaccination immunity and immunity acquired through past infection, breakthrough infections caused by Variants of Concern can still occur in COVID-19 cases. A patient in the study experienced breakthrough infections with the Alpha variant and the Delta variant, the latter resulting in severe illness even after boosting. The source of infection was established through clinical data and genetic sequencing.

FRONTIERS IN MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion

Petra Mlcochova et al.

Summary: The B.1.617.2 (Delta) variant of SARS-CoV-2 has lower sensitivity to antibodies and higher replication efficiency compared to other lineages, which may contribute to its dominance and reduced vaccine effectiveness, highlighting the need for continued infection control measures post-vaccination.

NATURE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Evolution patterns of SARS-CoV-2: Snapshot on its genome variants

Marta Giovanetti et al.

Summary: The novel coronavirus causing COVID-19 is a major threat with high morbidity and mortality rates, making it difficult to determine infectivity due to continuous evolution. It is urgent to study the virus deeply to understand its pathogenicity and virulence and develop effective therapeutic strategies. This article summarizes current knowledge on the virus's evolutionary and structural features to clarify its mutational pattern and potential role in the ongoing pandemic.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Zunyou Wu et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Medicine, General & Internal

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Dawei Wang et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Medicine, General & Internal

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Nanshan Chen et al.

LANCET (2020)

Add to Collection

Article Medicine, General & Internal

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Chaolin Huang et al.

LANCET (2020)

Add to Collection

Article Medicine, General & Internal

Clinical Characteristics of Coronavirus Disease 2019 in China

W. Guan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

Qun Li et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Microbiology

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Michael Letko et al.

NATURE MICROBIOLOGY (2020)

Add to Collection

Article Critical Care Medicine

Expression of the SARS-CoV-2 ACE2 Receptor in the Human Airway Epithelium

Haijun Zhang et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2020)

Add to Collection

Article Pharmacology & Pharmacy

The spike glycoprotein of the new coronavirus 2019-nCoV contains a furinlike cleavage site absent in CoV of the same clade

B. Coutard et al.

ANTIVIRAL RESEARCH (2020)

Add to Collection

Article Biochemistry & Molecular Biology

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Markus Hoffmann et al.

CELL (2020)

Add to Collection

Review Medicine, General & Internal

What we know so far: COVID-19 current clinical knowledge and research

Mary A. Lake

CLINICAL MEDICINE (2020)

Add to Collection

Review Oncology

Angiotensin-converting enzyme 2 (ACE2),SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19)

Arno R. Bourgonje et al.

JOURNAL OF PATHOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Bette Korber et al.

CELL (2020)

Add to Collection

Review Biochemistry & Molecular Biology

Extrapulmonary manifestations of COVID-19

Aakriti Gupta et al.

NATURE MEDICINE (2020)

Add to Collection

Article Multidisciplinary Sciences

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Alina Baum et al.

SCIENCE (2020)

Add to Collection

Article Immunology

SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function

Emma S. Winkler et al.

NATURE IMMUNOLOGY (2020)

Add to Collection

Article Immunology

Galectin-3 Interacts with the CHI3L1 Axis and Contributes to Hermansky-Pudlak Syndrome Lung Disease

Yang Zhou et al.

JOURNAL OF IMMUNOLOGY (2018)

Add to Collection

Article Microbiology

Topical application of aminoglycoside antibiotics enhances host resistance to viral infections in a microbiota-independent manner

Smita Gopinath et al.

NATURE MICROBIOLOGY (2018)

Add to Collection

Article Microbiology

Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2

Wenfei Song et al.

PLOS PATHOGENS (2018)

Add to Collection

Article Virology

Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis

Jean Kaoru Millet et al.

VIRUS RESEARCH (2015)

Add to Collection

Article Cell Biology

Chitinase 3-like 1 Suppresses Injury and Promotes Fibroproliferative Responses in Mammalian Lung Fibrosis

Yang Zhou et al.

SCIENCE TRANSLATIONAL MEDICINE (2014)

Add to Collection

Article Cell Biology

Chitinase 3-like 1 Regulates Cellular and Tissue Responses via IL-13 Receptor α2

Chuan Hua He et al.

CELL REPORTS (2013)

Add to Collection

Article Microbiology

Chitinase 3-like-1 Promotes Streptococcus pneumoniae Killing and Augments Host Tolerance to Lung Antibacterial Responses

Charles S. Dela Cruz et al.

CELL HOST & MICROBE (2012)

Add to Collection

Article Immunology

Chitinase 1 Is a Biomarker for and Therapeutic Target in Scleroderma-Associated Interstitial Lung Disease That Augments TGF-β1 Signaling

Chun Geun Lee et al.

JOURNAL OF IMMUNOLOGY (2012)

Add to Collection

Article Biochemistry & Molecular Biology

Role of Breast Regression Protein-39 in the Pathogenesis of Cigarette Smoke-Induced Inflammation and Emphysema

Hiroshi Matsuura et al.

AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2011)

Add to Collection

Review Physiology

Role of Chitin and Chitinase/Chitinase-Like Proteins in Inflammation, Tissue Remodeling, and Injury

Chun Geun Lee et al.

ANNUAL REVIEW OF PHYSIOLOGY, VOL 73 (2011)

Add to Collection

Review Allergy

Role of breast regression protein-39/YKL-40 in asthma and allergic responses

Chun Geun Lee et al.

ALLERGY ASTHMA & IMMUNOLOGY RESEARCH (2010)

Add to Collection

Article Immunology

Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis

Chun Geun Lee et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2009)

Add to Collection

Review Medicine, General & Internal

Chitin, Chitinases and Chitinase-like Proteins in Allergic Inflammation and Tissue Remodeling

Chun Geun Lee

YONSEI MEDICAL JOURNAL (2009)

Add to Collection

Article Medicine, Research & Experimental

Cigarette smoke selectively enhances viral PAMP- and virus-induced pulmonary innate immune and remodeling responses in mice

Min-Jong Kang et al.

JOURNAL OF CLINICAL INVESTIGATION (2008)

Add to Collection

Article Cardiac & Cardiovascular Systems

Serum YKL-40 levels in patients with coronary artery disease

Mine Kucur et al.

CORONARY ARTERY DISEASE (2007)

Add to Collection

Article Immunology

Early growth response gene 1-mediated apoptosis is essential for transforming growth factor β1-induced pulmonary fibrosis

CG Lee et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.